Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NRXP
stocks logo

NRXP

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
0.003
-100.32%
--
--
-0.013
-96.08%
--
--
0.020
-102.04%
Estimates Revision
The market is revising Downward the revenue expectations for NRx Pharmaceuticals, Inc. (NRXP) for FY2025, with the revenue forecasts being adjusted by -39.13% over the past three months. During the same period, the stock price has changed by -11.27%.
Revenue Estimates for FY2025
Revise Downward
down Image
-39.13%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+105.13%
In Past 3 Month
Stock Price
Go Down
down Image
-11.27%
In Past 3 Month
Wall Street analysts forecast NRXP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRXP is 33.00 USD with a low forecast of 25.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast NRXP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRXP is 33.00 USD with a low forecast of 25.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.440
sliders
Low
25.00
Averages
33.00
High
40.00
Current: 2.440
sliders
Low
25.00
Averages
33.00
High
40.00
H.C. Wainwright
H.C. Wainwright
initiated
$40
2025-09-08
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$40
2025-09-08
initiated
Reason
H.C. Wainwright initiated coverage of NRx Pharmaceuticals with a Buy rating and $40 price target. the company is combining novel therapeutics with integrated mental health care delivery to address acute suicidality in depression, the analyst tells investors in a research note. The firm believes NRx is positioned to become a leader in high-isk mood disorders and remains "significantly undervalued" at current share levels.
BTIG
Thomas Shrader
Buy
maintain
$21 -> $25
2025-08-25
Reason
BTIG
Thomas Shrader
Price Target
$21 -> $25
2025-08-25
maintain
Buy
Reason
BTIG analyst Thomas Shrader raised the firm's price target on NRx Pharmaceuticals to $25 from $21 and keeps a Buy rating on the shares. The company is making progress on most fronts, and with FDA acceptance for the NDA detailing preservative-free ketamine, on-label option for MDD, Major Depressive Disorder, and ASIB, Acute Suicidal Ideation and Behavior, is the next important event, the analyst tells investors in a research note.
BTIG
Thomas Schrader
Strong Buy
Initiates
$18
2025-04-02
Reason
BTIG
Thomas Schrader
Price Target
$18
2025-04-02
Initiates
Strong Buy
Reason
BTIG initiated coverage of NRx Pharmaceuticals with a Buy rating and $18 price target. NRx Pharmaceuticals is working broadly in suicidal ideation and behavior, a large area of unmet need that has seen essentially no improvement in treatment outcomes in 50 years, and is seeking to generate an FDA-approved version of IV ketamine to help standardize the treatment landscape, the analyst tells investors in a research note. The initial IV ketamine FDA submission package is supported by a collection of high-quality and controlled trials supporting the drug's activity in suicidal ideation and depressive symptoms, and BTIG sees this approach as reasonably likely to be enough for approval as the real-world evidence for this indication is significant and includes huge composite data sets collected across the current treatment landscape.
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$31
2025-03-31
Reason
D. Boral Capital
Jason Kolbert
Price Target
$31
2025-03-31
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$31
2025-03-24
Reason
D. Boral Capital
Jason Kolbert
Price Target
$31
2025-03-24
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$19
2025-03-20
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$19
2025-03-20
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for NRX Pharmaceuticals Inc (NRXP.O) is 35.26, compared to its 5-year average forward P/E of 0.53. For a more detailed relative valuation and DCF analysis to assess NRX Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.53
Current PE
35.26
Overvalued PE
12.20
Undervalued PE
-11.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.16
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
4.16
Undervalued EV/EBITDA
-3.83

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.16
Current PS
0.00
Overvalued PS
0.48
Undervalued PS
-0.17
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

NRXP News & Events

Events Timeline

(ET)
2025-12-04
11:00:00
Clearmind Doses First Participant with CMND-100 at Hadassah Medical Center
select
2025-12-03 (ET)
2025-12-03
07:10:00
NRx Pharmaceuticals Amends NRX-101 IND for Depression Treatment
select
2025-12-02 (ET)
2025-12-02
08:41:00
NRx Pharmaceuticals' KETAFREE Receives FDA Acknowledgment for ANDA Submission
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-03Globenewswire
NRx Amends NRX-101 Filing to Enhance Depression Treatment with TMS
  • Clinical Trial Advancement: NRx has amended its Investigational New Drug filing for NRX-101 to include its use with Transcranial Magnetic Stimulation (TMS) for depression treatment, which is expected to significantly enhance clinical response rates to 75% and remission rates to 40%, indicating substantial market potential.
  • Market Potential: By 2030, over 1 million Americans are projected to receive TMS treatment annually, creating a new market opportunity for NRX-101 that may exceed previous company expectations.
  • Drug Combination Advantage: NRX-101 combines low-dose D-cycloserine with lurasidone, with clinical trials showing over two-fold improvement in depression symptoms and fewer side effects, positioning it as a potential standard therapy in conjunction with TMS.
  • Expanded Access Policy: NRx has published an Expanded Access policy allowing physicians to provide NRX-101 to patients in need, further enhancing the company's competitive position in the depression treatment market.
[object Object]
Preview
9.0
12-03Newsfilter
NRx Amends NRX-101 Filing to Include TMS for Depression Treatment
  • Clinical Trial Progress: NRx has amended its Investigational New Drug filing for NRX-101 to include its use with Transcranial Magnetic Stimulation (TMS) for depression treatment, which is expected to significantly enhance treatment outcomes, particularly with a clinical response rate of 75% in suicidal depression patients.
  • Market Potential: By 2030, over 1 million Americans are expected to receive TMS treatment annually, creating a substantial new market for NRX-101, which could significantly boost the company's revenue from previously unanticipated commercial opportunities.
  • Efficacy Validation: Recent studies indicate that patients receiving D-cycloserine in conjunction with TMS experienced over a two-fold reduction in depressive symptoms, highlighting the drug's significant advantages in clinical applications and its potential to become a standard treatment option.
  • Innovative Drug Combination: NRX-101 combines D-cycloserine with lurasidone, which is already approved for depression treatment, potentially reducing side effect risks and increasing patient acceptance, thereby further driving market recognition.
[object Object]
Preview
9.0
12-02Newsfilter
NRx Receives FDA Acknowledgment for KETAFREE™ ANDA, Targeting July 2026 Approval
  • Application Progress: NRx's ANDA for KETAFREE™ has been acknowledged as 'substantially complete' by the FDA, with a target review completion date of July 29, 2026, which could significantly enhance the company's competitive position in the $750 million global ketamine market upon approval.
  • Product Innovation: KETAFREE™ is the first preservative-free ketamine formulation, addressing growing safety concerns in the market, and is expected to attract more clinical users and patients seeking safer alternatives.
  • Production Capacity: NRx has manufactured initial registration lots and is prepared to scale production to 1 million vials per month, ensuring rapid market supply post-approval and enhancing the company's revenue potential.
  • Strategic Alignment: The development of KETAFREE™ aligns with the FDA's initiatives to remove toxic substances, demonstrating NRx's commitment to drug safety, which may provide the company with a long-term market advantage.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is NRX Pharmaceuticals Inc (NRXP) stock price today?

The current price of NRXP is 2.44 USD — it has increased 1.24 % in the last trading day.

arrow icon

What is NRX Pharmaceuticals Inc (NRXP)'s business?

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.

arrow icon

What is the price predicton of NRXP Stock?

Wall Street analysts forecast NRXP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRXP is 33.00 USD with a low forecast of 25.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is NRX Pharmaceuticals Inc (NRXP)'s revenue for the last quarter?

NRX Pharmaceuticals Inc revenue for the last quarter amounts to 242.00K USD, decreased % YoY.

arrow icon

What is NRX Pharmaceuticals Inc (NRXP)'s earnings per share (EPS) for the last quarter?

NRX Pharmaceuticals Inc. EPS for the last quarter amounts to -0.26 USD, increased 73.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for NRX Pharmaceuticals Inc (NRXP)'s fundamentals?

The market is revising Downward the revenue expectations for NRx Pharmaceuticals, Inc. (NRXP) for FY2025, with the revenue forecasts being adjusted by -39.13% over the past three months. During the same period, the stock price has changed by -11.27%.
arrow icon

How many employees does NRX Pharmaceuticals Inc (NRXP). have?

NRX Pharmaceuticals Inc (NRXP) has 0 emplpoyees as of December 05 2025.

arrow icon

What is NRX Pharmaceuticals Inc (NRXP) market cap?

Today NRXP has the market capitalization of 68.56M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free